Cellectis (NASDAQ:CLLS) Posts Earnings Results, Beats Estimates By $0.04 EPS

Cellectis (NASDAQ:CLLS) issued its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.04, Zacks reports. Cellectis had a negative net margin of 102.34% and a negative return on equity of 94.19%. The company had revenue of $6.90 million for the quarter, compared to the consensus estimate of $11.05 million.

Cellectis Trading Down 0.6%

CLLS stock opened at $3.10 on Friday. Cellectis has a 12 month low of $2.35 and a 12 month high of $5.48. The firm’s 50-day moving average is $3.03 and its 200 day moving average is $3.36. The company has a market capitalization of $311.05 million, a PE ratio of -4.77 and a beta of 2.92. The company has a debt-to-equity ratio of 1.61, a current ratio of 1.37 and a quick ratio of 1.37.

Wall Street Analyst Weigh In

Several brokerages have issued reports on CLLS. Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research report on Friday, July 17th. Barclays assumed coverage on Cellectis in a report on Thursday, May 28th. They issued an “overweight” rating and a $9.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $7.00.

Hedge Funds Weigh In On Cellectis

A number of institutional investors have recently modified their holdings of the stock. Global Retirement Partners LLC purchased a new stake in shares of Cellectis in the fourth quarter valued at approximately $34,000. Acadian Asset Management LLC increased its holdings in Cellectis by 132.9% during the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 26,461 shares during the period. Virtu Financial LLC bought a new stake in Cellectis during the 3rd quarter valued at $72,000. Millennium Management LLC raised its position in Cellectis by 61.9% during the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 22,080 shares in the last quarter. Finally, Citadel Advisors LLC bought a new stake in Cellectis during the 3rd quarter valued at $633,000. 63.90% of the stock is owned by hedge funds and other institutional investors.

About Cellectis

Cellectis is a clinical?stage biopharmaceutical company specializing in the development of gene?edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T?cell (CAR?T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off?the?shelf immunotherapies.